Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Jay R. Khambhati, MD
Retrospective Analysis
Long-Term Clinical Outcomes After TAVR With Balloon-Expandable Versus Self-Expanding Valves
11/10/2023

CLD talks with Jay R. Khambhati, MD, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts.

CLD talks with Jay R. Khambhati, MD, ...
Researchers compared longitudinal clinical outcomes in patients undergoing TAVR with balloon expandable versus self-expanding valves in patients who received either therapy from 2014 to 2020.
Researchers compared longitudinal clinical outcomes in patients undergoing TAVR with balloon expandable versus self-expanding valves in patients who received either therapy from 2014 to 2020.
Researchers compared...
11/10/2023
Cath Lab Digest
Dr. Josep Rodés-Cabau
Clinical Trial Update: Small Aortic Annulus
The VIVA Trial: TAVR Versus SAVR in Patients With Severe Aortic Stenosis and Small Aortic Annuli
10/31/2023

Report from TCT: A presentation by Josep Rodés-Cabau, MD, Quebec Heart and Lung Institute, on behalf of the VIVA trial investigators.

Report from TCT: A presentation by Jo...
"TAVR and SAVR represent a valid alternative for treating patients with aortic stenosis and small aortic annulus,” concluded Dr. Rodés-Cabau.
"TAVR and SAVR represent a valid alternative for treating patients with aortic stenosis and small aortic annulus,” concluded Dr. Rodés-Cabau.
"TAVR and SAVR represent a valid...
10/31/2023
Cath Lab Digest
Philippe Généreux, MD
aortic stenosis
Novel Research on Aortic Stenosis From egnite, Inc.’s Database Presented at Transcatheter Cardiovascular Therapeutics Conference 2023
10/25/2023
“This research is the first of its kind to look at such a large cohort of AS patients over a four-year span. Findings serve as a stark reminder of the poor prognosis associated with untreated AS irrespective of severity, suggesting patients...
“This research is the first of its kind to look at such a large cohort of AS patients over a four-year span. Findings serve as a stark reminder of the poor prognosis associated with untreated AS irrespective of severity, suggesting patients...
“This research is the first of...
10/25/2023
Cath Lab Digest
ShortCut device
Leaflet Modification
The ShortCut Pivotal Trial: A Dedicated Valve Leaflet Splitting Device
10/25/2023

Report from TCT: A presentation by Susheel Kodali, MD, Professor of Medicine, Avanessians Associate Professor of Cardiology, Columbia University Medical Center, New York Presbyterian Hospital

Report from TCT: A presentation by Su...
The ShortCut leaflet splitting procedure can be done in anywhere from five to 10 minutes, says Dr. Susheel Kodali, and patients typically remain stable during the procedure.
The ShortCut leaflet splitting procedure can be done in anywhere from five to 10 minutes, says Dr. Susheel Kodali, and patients typically remain stable during the procedure.
The ShortCut leaflet splitting...
10/25/2023
Cath Lab Digest
Mohan EPLD Watchman LAAO
Clinical Trial Update: TAVR & LAAO
WATCH TAVR Trial Finds That Atrial Fibrillation Patients Undergoing TAVR and Watchman Procedures Together Have Similar Outcomes to Using Blood Thinners After TAVR
10/24/2023

Cleveland Clinic News

Cleveland Clinic News
The multicenter, randomized WATCH-TAVR trial set out to investigate the safety of implantation of the WATCHMAN 2.5 device at the time of TAVR and to compare the efficacy of WATCHMAN LAAO with contemporary medical therapy in this population of...
The multicenter, randomized WATCH-TAVR trial set out to investigate the safety of implantation of the WATCHMAN 2.5 device at the time of TAVR and to compare the efficacy of WATCHMAN LAAO with contemporary medical therapy in this population of...
The multicenter, randomized...
10/24/2023
Cath Lab Digest
Sapien 3 Valve (Edwards)
Clinical Trial Update: Sapien 3 THV
Five-Year Data From PARTNER 3 Trial Demonstrate Excellent Survival for Patients Receiving Edwards Sapien 3 Valve
10/24/2023

Edwards Lifesciences News

Edwards Lifesciences News
"The five-year follow-up findings from the PARTNER 3 trial reaffirm the clinical outcome benefits and bioprosthetic valve durability of SAPIEN 3 TAVR as a meaningful alternative to surgical therapy for low-risk severe, symptomatic AS...
"The five-year follow-up findings from the PARTNER 3 trial reaffirm the clinical outcome benefits and bioprosthetic valve durability of SAPIEN 3 TAVR as a meaningful alternative to surgical therapy for low-risk severe, symptomatic AS...
"The five-year follow-up...
10/24/2023
Cath Lab Digest
clinical trial update: aortic regurgitation
JenaValve Announces Late-Breaking Data From the ALIGN-AR Pivotal Trial Meeting Safety and Efficacy Endpoints
10/24/2023

JenaValve Technologies, Inc. News

JenaValve Technologies, Inc. News ...
The trial met prespecified non-inferiority criteria for its primary safety endpoint and primary efficacy endpoint. Outcomes were presented by Dr. Vinod Thourani (Piedmont Heart Institute, Atlanta, GA).
The trial met prespecified non-inferiority criteria for its primary safety endpoint and primary efficacy endpoint. Outcomes were presented by Dr. Vinod Thourani (Piedmont Heart Institute, Atlanta, GA).
The trial met prespecified...
10/24/2023
Cath Lab Digest
Benjamin Z. Galper, MD, MPH
referral pathways
The TAVR DELAY Registry: Rates of Early Referral to a Structural Heart Team in a Large Integrated Healthcare System
10/24/2023

Benjamin Z. Galper, MD, MPH, FACC, FSCAI

Chief of Cardiology, MAPMG NOVA service area; Director, MAPMG Structural Heart Disease Program; Medical Director, Structural Heart Disease Program, Virginia Hospital Center; Co-Medical Director, Louise Olmstead Sands Cardiac Catheterization Laboratory, Virginia Hospital Center

Dr. Galper can be contacted at benjamin.z.galper@kp.org.

Benjamin Z. Galper, MD, MPH, FACC, FS...
“TAVR is an amazing technology," says Benjamin Z. Galper, MD, MPH. "But for some reason, TAVR is not being disseminated in the population as widely as it should be, given that we have so many structural heart programs across the country. Why...
“TAVR is an amazing technology," says Benjamin Z. Galper, MD, MPH. "But for some reason, TAVR is not being disseminated in the population as widely as it should be, given that we have so many structural heart programs across the country. Why...
“TAVR is an amazing technology,"...
10/24/2023
Cath Lab Digest
Medtronic Evolut PRO
Clinical Trial Update: Self-Expanding THV
Medtronic Evolut TAVR Platform Outperforms Surgery With Sustained Valve Performance for Low-Risk Patients at Four Years
10/24/2023

Medtronic News

Medtronic News
Since the approval of TAVR in low-risk surgical patients, there is an ongoing need for evidence to better understand the intermediate and longer-term durability of TAVR devices of different designs.
Since the approval of TAVR in low-risk surgical patients, there is an ongoing need for evidence to better understand the intermediate and longer-term durability of TAVR devices of different designs.
Since the approval of TAVR in...
10/24/2023
Cath Lab Digest
OpSens SavvyWire
Clinical Trial Update: SavvyWire
OpSens Announces Positive Clinical Results From SAFE-TAVI Study With SavvyWire in Europe
10/24/2023

OpSens News

OpSens News
"SAFE-TAVI Clinical Study: SavvyWire Efficacy and Safety in TAVI Procedures" will be presented on Wed, Oct 25, at 10:09am PST, at Moderated Abstracts Station 2 – Emerging Clinical Science & Research, Hall A, Exhibition Level, Moscone South
"SAFE-TAVI Clinical Study: SavvyWire Efficacy and Safety in TAVI Procedures" will be presented on Wed, Oct 25, at 10:09am PST, at Moderated Abstracts Station 2 – Emerging Clinical Science & Research, Hall A, Exhibition Level, Moscone South
"SAFE-TAVI Clinical Study:...
10/24/2023
Cath Lab Digest
Prof. Anthony Walton, MBBS, FRACP, FCSANZ
Hemostasis & Bleeding Reduction
ACE-PROTAVI: Safety and Efficacy of Protamine in TAVI for Prevention of Bleeding Complications
10/24/2023

Report from TCT: A presentation by Prof. Anthony Walton, MBBS, FRACP, FCSANZ, Epworth Hospital, Alfred Health, Richmond, Victoria, Australia

Report from TCT: A presentation by Pr...
“Our conclusion,” said Prof. Tony Walton, “was that routine protamine administration should be considered in all patients undergoing TAVI, unless a recent coronary intervention has been performed.”
“Our conclusion,” said Prof. Tony Walton, “was that routine protamine administration should be considered in all patients undergoing TAVI, unless a recent coronary intervention has been performed.”
“Our conclusion,” said Prof....
10/24/2023
Cath Lab Digest
Ong JIC May 2021
Research Focus
A Look at TAVR Research at TCT 2023
10/21/2023

From Cath Lab Digest's TAVR@TCT 2023 Newsroom

From Cath Lab Digest's TAVR@TCT 2023 ...
With several hotly anticipated late-breaking clinical trial results centering around transcatheter aortic valve replacement (TAVR), the 2023 TCT meeting, held October 23-26 in San Francisco, California, promises attendees a deep dive into the...
With several hotly anticipated late-breaking clinical trial results centering around transcatheter aortic valve replacement (TAVR), the 2023 TCT meeting, held October 23-26 in San Francisco, California, promises attendees a deep dive into the...
With several hotly anticipated...
10/21/2023
Cath Lab Digest
conference coverage
TAVR@TCT: 2023 Late-Breaking Clinical Trials Announced
09/20/2023

TCT News

TCT News
Cath Lab Digest's TCT 2023 Newsroom will provide a special focus on TAVR. The Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium will take place October 23-26 in San Francisco, California.
Cath Lab Digest's TCT 2023 Newsroom will provide a special focus on TAVR. The Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium will take place October 23-26 in San Francisco, California.
Cath Lab Digest's TCT 2023...
09/20/2023
Cath Lab Digest

Find More at the TVT Structural Heart Summit Newsroom

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement